the RELPEC Group

Response to the Letter Regarding “Methodological Considerations in Real‐World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma”

Data supporting the findings of this study are available from the corresponding author upon reasonable request, subject to institutional review board approval and execution of appropriate data sharing agreements.